ResMed (NYSE: RMD), a medical device company focused on breathing disorders, reported its fiscal fourth-quarter and full-year 2019 results on Thursday.
Revenue grew 13% when compared to the year-ago period, which represents yet another sequential acceleration on a sequential basis. However, expenses remain elevated as the company continues to integrate a handful of recent acquisitions. The net result is very little growth on the bottom line.
Metric
Quelle Fool.com